Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose? / Boehncke, W-H; Schön, M P; Girolomoni, G; Giromolomi, G; Griffiths, C; Bos, J D; Thestrup-Pedersen, K; Cavani, A; Nestle, F; Bonish, B K; Campbell, J J; Brakebusch, C; Nickoloff, B.

I: Experimental Dermatology, Bind 14, Nr. 1, 2005, s. 70-80.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Boehncke, W-H, Schön, MP, Girolomoni, G, Giromolomi, G, Griffiths, C, Bos, JD, Thestrup-Pedersen, K, Cavani, A, Nestle, F, Bonish, BK, Campbell, JJ, Brakebusch, C & Nickoloff, B 2005, 'Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?', Experimental Dermatology, bind 14, nr. 1, s. 70-80. https://doi.org/10.1111/j.0906-6705.2005.290a.x

APA

Boehncke, W-H., Schön, M. P., Girolomoni, G., Giromolomi, G., Griffiths, C., Bos, J. D., Thestrup-Pedersen, K., Cavani, A., Nestle, F., Bonish, B. K., Campbell, J. J., Brakebusch, C., & Nickoloff, B. (2005). Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose? Experimental Dermatology, 14(1), 70-80. https://doi.org/10.1111/j.0906-6705.2005.290a.x

Vancouver

Boehncke W-H, Schön MP, Girolomoni G, Giromolomi G, Griffiths C, Bos JD o.a. Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose? Experimental Dermatology. 2005;14(1):70-80. https://doi.org/10.1111/j.0906-6705.2005.290a.x

Author

Boehncke, W-H ; Schön, M P ; Girolomoni, G ; Giromolomi, G ; Griffiths, C ; Bos, J D ; Thestrup-Pedersen, K ; Cavani, A ; Nestle, F ; Bonish, B K ; Campbell, J J ; Brakebusch, C ; Nickoloff, B. / Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?. I: Experimental Dermatology. 2005 ; Bind 14, Nr. 1. s. 70-80.

Bibtex

@article{a67f0810589411dd8d9f000ea68e967b,
title = "Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?",
abstract = "In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.",
author = "W-H Boehncke and Sch{\"o}n, {M P} and G Girolomoni and G Giromolomi and C Griffiths and Bos, {J D} and K Thestrup-Pedersen and A Cavani and F Nestle and Bonish, {B K} and Campbell, {J J} and C Brakebusch and B Nickoloff",
note = "Keywords: Anti-Inflammatory Agents; Apoptosis; Cell Adhesion; Cell Adhesion Molecules; Cell Movement; Dermatitis; Humans; Immunosuppressive Agents; Inflammation; Leukocyte Rolling; Leukocytes; Lymphocyte Activation; Models, Animal; Models, Immunological; Skin Diseases",
year = "2005",
doi = "10.1111/j.0906-6705.2005.290a.x",
language = "English",
volume = "14",
pages = "70--80",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?

AU - Boehncke, W-H

AU - Schön, M P

AU - Girolomoni, G

AU - Giromolomi, G

AU - Griffiths, C

AU - Bos, J D

AU - Thestrup-Pedersen, K

AU - Cavani, A

AU - Nestle, F

AU - Bonish, B K

AU - Campbell, J J

AU - Brakebusch, C

AU - Nickoloff, B

N1 - Keywords: Anti-Inflammatory Agents; Apoptosis; Cell Adhesion; Cell Adhesion Molecules; Cell Movement; Dermatitis; Humans; Immunosuppressive Agents; Inflammation; Leukocyte Rolling; Leukocytes; Lymphocyte Activation; Models, Animal; Models, Immunological; Skin Diseases

PY - 2005

Y1 - 2005

N2 - In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.

AB - In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.

U2 - 10.1111/j.0906-6705.2005.290a.x

DO - 10.1111/j.0906-6705.2005.290a.x

M3 - Journal article

C2 - 15660923

VL - 14

SP - 70

EP - 80

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 1

ER -

ID: 5141206